198 related articles for article (PubMed ID: 37587471)
1. Platelet-derived circRNAs signature in patients with gastroenteropancreatic neuroendocrine tumors.
Campolo F; Sesti F; Feola T; Puliani G; Faggiano A; Tarsitano MG; Tenuta M; Hasenmajer V; Ferretti E; Verrico M; Gianfrilli D; Venneri MA; Isidori AM; Giannetta E
J Transl Med; 2023 Aug; 21(1):548. PubMed ID: 37587471
[TBL] [Abstract][Full Text] [Related]
2. Identification and validation of core genes in tumor-educated platelets for human gastrointestinal tumor diagnosis using network-based transcriptomic analysis.
Jiang Y; He J; Wang X; Liu C; Zhou W; Liu D; Guo Z; Liu K
Platelets; 2023 Dec; 34(1):2212071. PubMed ID: 37212262
[TBL] [Abstract][Full Text] [Related]
3. The Analysis of Platelet-Derived circRNA Repertoire as Potential Diagnostic Biomarker for Non-Small Cell Lung Cancer.
D'Ambrosi S; Visser A; Antunes-Ferreira M; Poutsma A; Giannoukakos S; Sol N; Sabrkhany S; Bahce I; Kuijpers MJE; Oude Egbrink MGA; Griffioen AW; Best MG; Koppers-Lalic D; Oudejans C; Würdinger T
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572871
[TBL] [Abstract][Full Text] [Related]
4. Presence of sst5TMD4, a truncated splice variant of the somatostatin receptor subtype 5, is associated to features of increased aggressiveness in pancreatic neuroendocrine tumors.
Sampedro-Núñez M; Luque RM; Ramos-Levi AM; Gahete MD; Serrano-Somavilla A; Villa-Osaba A; Adrados M; Ibáñez-Costa A; Martín-Pérez E; Culler MD; Marazuela M; Castaño JP
Oncotarget; 2016 Feb; 7(6):6593-608. PubMed ID: 26673010
[TBL] [Abstract][Full Text] [Related]
5. Clinical and functional implication of the components of somatostatin system in gastroenteropancreatic neuroendocrine tumors.
Herrera-Martínez AD; Gahete MD; Pedraza-Arevalo S; Sánchez-Sánchez R; Ortega-Salas R; Serrano-Blanch R; Luque RM; Gálvez-Moreno MA; Castaño JP
Endocrine; 2018 Feb; 59(2):426-437. PubMed ID: 29196939
[TBL] [Abstract][Full Text] [Related]
6. PRRT genomic signature in blood for prediction of
Bodei L; Kidd MS; Singh A; van der Zwan WA; Severi S; Drozdov IA; Cwikla J; Baum RP; Kwekkeboom DJ; Paganelli G; Krenning EP; Modlin IM
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(7):1155-1169. PubMed ID: 29484451
[TBL] [Abstract][Full Text] [Related]
7. Baseline tumor growth rate highlights the heterogeneity of well differentiated gastroenteropancreatic neuroendocrine tumors and predicts for increases in Ki67 index over time.
Wang SJ; Whitman J; Paciorek A; Le BK; Nakakura EK; Behr SC; Joseph N; Zhang L; Hope TA; Bergsland EK
J Neuroendocrinol; 2023 Apr; 35(4):e13260. PubMed ID: 37002881
[TBL] [Abstract][Full Text] [Related]
8. Cardio-Metabolic Indices and Metabolic Syndrome as Predictors of Clinical Severity of Gastroenteropancreatic Neuroendocrine Tumors.
Barrea L; Muscogiuri G; Modica R; Altieri B; Pugliese G; Minotta R; Faggiano A; Colao A; Savastano S
Front Endocrinol (Lausanne); 2021; 12():649496. PubMed ID: 33815296
[TBL] [Abstract][Full Text] [Related]
9. Real-world comparison of healthcare resource utilization and costs of [
Cox T; O'Connell M; Leeuwenkamp O; Palimaka S; Reed N
Curr Med Res Opin; 2022 Aug; 38(8):1305-1317. PubMed ID: 35418254
[TBL] [Abstract][Full Text] [Related]
10. Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors.
Park C; Ha SY; Kim ST; Kim HC; Heo JS; Park YS; Lauwers G; Lee J; Kim KM
Oncotarget; 2016 Jan; 7(4):4024-35. PubMed ID: 26684240
[TBL] [Abstract][Full Text] [Related]
11. A Comprehensive Assessment of the Role of miRNAs as Biomarkers in Gastroenteropancreatic Neuroendocrine Tumors.
Malczewska A; Kidd M; Matar S; Kos-Kudla B; Modlin IM
Neuroendocrinology; 2018; 107(1):73-90. PubMed ID: 29566385
[TBL] [Abstract][Full Text] [Related]
12. The predictive impact of dual somatostatin receptor/fluorodeoxyglucose (FDG) positron emission tomography (PET) in metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs): review of literature and a single institution experience.
Mohamed A; Asa SL; Lee Z; Tirumani SH; Li Q; Avril N; Bajor D; Mahipal A; Chakrabarti S; Selfridge JE; Kardan A
J Gastrointest Oncol; 2023 Apr; 14(2):1087-1094. PubMed ID: 37201086
[TBL] [Abstract][Full Text] [Related]
13. Evaluating gastroenteropancreatic neuroendocrine tumors through microRNA sequencing.
Panarelli N; Tyryshkin K; Wong JJM; Majewski A; Yang X; Scognamiglio T; Kim MK; Bogardus K; Tuschl T; Chen YT; Renwick N
Endocr Relat Cancer; 2019 Jan; 26(1):47-57. PubMed ID: 30021866
[TBL] [Abstract][Full Text] [Related]
14. Circular RNA Sequencing of Maternal Platelets: A Novel Tool for the Identification of Pregnancy-Specific Biomarkers.
Oudejans C; Manders V; Visser A; Keijser R; Min N; Poutsma A; Mulders J; van den Berkmortel T; Wigman DJ; Blanken B; Jongejan A; Pajkrt E; de Boer M; Sistermans EA; Sie D; Best MG; Würdinger T; Afink G
Clin Chem; 2021 Mar; 67(3):508-517. PubMed ID: 33257975
[TBL] [Abstract][Full Text] [Related]
15. Epidemiologic Trends of and Factors Associated With Overall Survival for Patients With Gastroenteropancreatic Neuroendocrine Tumors in the United States.
Xu Z; Wang L; Dai S; Chen M; Li F; Sun J; Luo F
JAMA Netw Open; 2021 Sep; 4(9):e2124750. PubMed ID: 34554237
[TBL] [Abstract][Full Text] [Related]
16. High VEGF serum values are associated with locoregional spread of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Cigrovski Berković M; Čačev T; Catela Ivković T; Marout J; Ulamec M; Zjačić-Rotkvić V; Kapitanović S
Mol Cell Endocrinol; 2016 Apr; 425():61-8. PubMed ID: 26805636
[TBL] [Abstract][Full Text] [Related]
17. Analysis of 320 gastroenteropancreatic neuroendocrine tumors identifies TS expression as independent biomarker for survival.
Lee HS; Chen M; Kim JH; Kim WH; Ahn S; Maeng K; Allegra CJ; Kaye FJ; Hochwald SN; Zajac-Kaye M
Int J Cancer; 2014 Jul; 135(1):128-37. PubMed ID: 24347111
[TBL] [Abstract][Full Text] [Related]
18. Comparing Somatostatin Analogs in the Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors.
Allaw MB; Switchenko JM; Khalil L; Wu C; Alese OB; Akce M; Draper A; Jones AT; El-Rayes B; Shaib W
Oncology; 2022; 100(3):131-139. PubMed ID: 35078191
[TBL] [Abstract][Full Text] [Related]
19. What have we learnt from the past - would treatment decisions for GEP-NET patients differ between 2012 to 2016 by the new recommendations in 2022?
Stiefel R; Lehmann K; Winder T; Siebenhüner AR
BMC Cancer; 2023 Feb; 23(1):148. PubMed ID: 36782152
[TBL] [Abstract][Full Text] [Related]
20. Impact of Nutritional Status on Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Aggressiveness.
Barrea L; Altieri B; Muscogiuri G; Laudisio D; Annunziata G; Colao A; Faggiano A; Savastano S
Nutrients; 2018 Dec; 10(12):. PubMed ID: 30513732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
